

Supplementary Table 2: Changes in lymphocyte subpopulations in peripheral blood of chronic spontaneous urticaria patients before and 6 months after omalizumab treatment (n=9)

Subpopulations	Parent	Percentage (%) before Omalizumab treatment		Percentage (%) after Omalizumab treatment		Pre treatment VS post-treatment (p)
CD4⁺ T lymphocytes	T cells	44.9	[39.3-55.2]	43.5	[32.9-56]	0.90
CD4 T naïve	T CD4	42.3	[30.2-60.2]	40.7	[27.6-51.7]	0.98
CD4 T central memory	T CD4	38.2	[23.7-50.5]	40.4	[33.3-51.7]	0.62
CD4 T effector memory	T CD4	17.3	[6.8-26.3]	16.6	[10.1-23.4]	0.81
CD4 T EMRA	T CD4	2.2	[0.2-8.3]	2.2	[0.2-5.1]	0.70
CD4 T DR+CD38+	T CD4	0.8	[0.2-1.1]	1.0	[0.5-1.3]	0.38
CD4 T DR+CD38-	T CD4	1.9	[0.5-5.6]	1.3	[0.4-2]	0.39
CD4 T DR-CD38+	T CD4	39.3	[13.4-66.2]	34.9	[15.8-60]	0.64
Th1 CM	T CD4 CM	14.4	[9.7-21.3]	15.6	[9.8-24.9]	0.44
Th1 EM	T CD4 EM	8.5	[2.9-12.1]	9.3	[4.8-15.1]	0.79
Th2 CM	T CD4 CM	10.2	[5.3-21.1]	9.6	[4.9-14.9]	0.80
Th2 EM	T CD4 EM	3.1	[0.3-13]	3.4	[0.9-6.3]	0.40
CD8⁺ T lymphocytes	T cells	25.5	[21.7-27.5]	25.3	[20.7-40.4]	0.64
CD8 T naïve	T CD8	29.6	[10.7-49.1]	28.0	[10.3-48.2]	0.62
CD8 T central memory	T CD8	14	[3.7-21.2]	16.5	[10.6-23.9]	0.57
CD8 T effector memory	T CD8	17.5	[7.3-35.9]	15.6	[7.3-24.4]	0.90
CD8 T EMRA	T CD8	38.9	[10.8-66.4]	39.8	[6.6-46.8]	ns
CD8 T DR+CD38+	T CD8	2.7	[0.2-6.9]	2.8	[2-6.3]	0.36
CD8 T DR+CD38-	T CD8	5.3	[1.5-9.4]	4.1	[0.3-6.9]	0.52
CD8 T DR-CD38+	T CD8	14.1	[7.2-27]	16.6	[5.4-38.6]	0.96